secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2026-05-19T11:00:17+00:00
Accession:  0001193125-26-229610
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio selects KRRO-111 for AATD; pre-clinical results show >90% RNA editing
-------------------------------------------------------------------------------

- KRRO-111 is a GalNAc-conjugated oligonucleotide delivered subcutaneously for AATD.
- In vivo editing >90% of SERPINA1 transcript, translating to ~90% repaired functional AAT protein in mouse model.
- Repeated dosing nearly eliminated active Z-protein production; pre-existing aggregates progressively cleared.
- Company plans to present additional KRRO-111 data at future scientific meeting.
- CEO noted well-capitalized position to advance both KRRO-111 and KRRO-121 toward clinical data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526229610/0001193125-26-229610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526229610/krro-20260519.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-229610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer